EUVIMEDEUVIMED entdecken
Multizentrische Studie

Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis

Roberto Contieri, Letizia Maria Ippolita Jannello, Mihai Dorin Vartolomei, Beat Roth, Roberto Bianchi, Giuseppe Fallara, Marco Tozzi, Martina Maggi, Francesco Chierigo, Francesco Pellegrino, Ludovica Cella, Alessandro Uleri und 48 weitere

International Urology and Nephrology · 2026

DOI: 10.1007/s11255-025-04946-9 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Urology and Nephrology, 2026. Verfasst von Roberto Contieri und 59 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Istituto Nazionale Tumori di Napoli IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 52, 80131, Naples, NA, Italy. Roberto.…. Hauptthemen laut MEDLINE: Mitomycin, Non-Muscle Invasive Bladder Neoplasms, Antibiotics, Antineoplastic, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: While mitomycin C (MMC) is widely used for intravesical therapy, the optimal maintenance regimen for non-muscle invasive bladder cancer (NMIBC) remains unclear. This study assessed the impact of MMC maintenance on recurrence-free survival (RFS) in patients with intermediate-risk Ta NMIBC and aimed to identify the optimal number of instillations for improved outcomes. METHODS: We conducted a retrospective multicenter analysis of patients with Ta NMIBC treated with transurethral resection and adjuvant MMC across 13 Italian centers (2010-2023). Patients were grouped based on MMC maintenance duration: no maintenance, short-term (≤ 6 instillations), and long-term (> 6 instillations). Kaplan-Meier curves, Cox regression, and CART analysis were used to evaluate RFS and high-grade RFS (HG-RFS). RESULTS: Among 292 patients included, maintenance therapy significantly improved 2-year and 3-year RFS compared to no maintenance (78% vs. 55% and 67% vs. 30%, respectively; p 6 instillations as the threshold for optimal benefit. Long-term maintenance was associated with a lower risk of recurrence (HR 0.23 vs. no maintenance; HR 0.39 vs. short-term; both p 6 instillations) significantly prolongs RFS in patients with Ta NMIBC. These findings suggest that extended MMC regimens may improve patients' outcomes and should be considered in clinical practice. Prospective studies are needed to confirm these results and guide evidence-based treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MitomycinNon-Muscle Invasive Bladder NeoplasmsAntibiotics, AntineoplasticUrinary Bladder NeoplasmsHumansRetrospective StudiesFemaleMaleAgedTransurethral Resection of BladderAdministration, IntravesicalMiddle AgedTime FactorsMaintenance Chemotherapy

Stichwörter der Autor:innen

Bladder cancerInstillation durationLandmark analysisMitomycin CTa NMIBC

Substanzen

MitomycinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Department of Urology, Istituto Nazionale Tumori di Napoli IRCCS Fondazione "G. Pascale", Via Mariano Semmola, 52, 80131, Naples, NA, Italy. Roberto.contieri@istitutotumori.na.it.
  • Università degli Studi di Milano, Milan, Italy.
  • Unity of Urology, Department of Health Science, University of Milan, ASST Santi Paolo and Carlo, Via A. Di Rudini 8, 20142, Milan, Italy.
  • Department of Urology, University of Bern, Bern, Switzerland.
  • Doctoral School, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.

Zitieren

APA

Contieri, R., Jannello, L. M. I., Vartolomei, M. D., Roth, B., Bianchi, R., Fallara, G., Tozzi, M., Maggi, M., Chierigo, F., Pellegrino, F., Cella, L., Uleri, A., Da Pozzo, L., Claps, F., Aveta, A., Spena, G., Checcucci, E., Gatti, C., Bove, P., …, & Catellani, M. (2026). Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis. International Urology and Nephrology. https://doi.org/10.1007/s11255-025-04946-9

Vancouver

Contieri R, Jannello LMI, Vartolomei MD, Roth B, Bianchi R, Fallara G, et al. Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis. International Urology and Nephrology. 2026. doi:10.1007/s11255-025-04946-9

BibTeX
@article{Contieri2026,
  author = {Contieri, Roberto and Jannello, Letizia Maria Ippolita and Vartolomei, Mihai Dorin and Roth, Beat and Bianchi, Roberto and Fallara, Giuseppe and Tozzi, Marco and Maggi, Martina and Chierigo, Francesco and Pellegrino, Francesco and Cella, Ludovica and Uleri, Alessandro and Da Pozzo, Luigi and Claps, Francesco and Aveta, Achille and Spena, Gianluca and Checcucci, Enrico and Gatti, Cecilia and Bove, Pierluigi and Vedovo, Francesca and Busetto, Gian Maria and Falagario, Ugo and Mastroianni, Riccardo and Tedde, Alessandro and Madonia, Massimo and Di Tonno, Pasquale and Lucarelli, Giuseppe and Forte, Saverio and Russo, Giorgio Ivan and Verweij, Fabrizio and Racioppi, Marco and Bizzarri, Francesco Pio and Borghesi, Marco and Rinaldi, Marco and Zattoni, Fabio and Boeri, Luca and De Lorenzis, Elisa and Conti, Andrea and Cerruto, Maria Angela and Crocetto, Felice and Simone, Giuseppe and Di Stasi, Savino Mauro and De Nunzio, Cosimo and Carmignani, Luca and Liguori, Giovanni and Porreca, Angelo and Barone, Biagio and Montanari, Emanuele and Giancarlo, Albo and Antonelli, Alessandro and Veccia, Alessandro and Moro, Fabrizio Dal and Carrieri, Giuseppe and Cormio, Luigi and Terrone, Carlo and Porpiglia, Francesco and Perdonà, Sisto and Rocco, Bernardo and Hurle, Rodolfo and Catellani, Michele},
  title = {Defining the optimal duration of maintenance mitomycin C in intermediate-risk Ta NMIBC: a multicenter retrospective landmark analysis},
  journal = {International Urology and Nephrology},
  year = {2026},
  doi = {10.1007/s11255-025-04946-9}
}
Kostenlos starten →